30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Strategic Initiatives

Seikagaku Enters U.S. Distribution Agreement with Zimmer Biomet for VISCO-3 -

Seikagaku entered into an exclusive agreement with Zimmer Biomet for U.S. distribution of VISCO-3™, a 3-injection hyaluronic acid-based viscosupplement for the treatment of knee osteoarthritis pain.

VISCO-3 received FDA Premarket Approval in 4Q15. Zimmer Biomet and Seikagaku have partnered on U.S. sales of Seikagaku's Gel-One® single-injection viscosupplement since 2012. Seikagaku's SUPARTZ FX® 5-injection treatment is marketed by Bioventus.

Sources: Seikagaku Corporation; FDA.gov; ORTHOWORLD Inc.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.